Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: subgroup analysis of patients with type 2 diabetes from China coronary secondary prevention study (CCSPS).

Abstract

Lipid-lowering therapy has been proven to reduce macrovascular complications of type 2 diabetes. Xuezhikang is an extract of cholestin and has a markedly modulating effect on lipids, but the effect of xuezhikang on reducing coronary events in diabetic patients with coronary heart disease (CHD) is less clear. A total of 591 diabetic patients with CHD were randomized to the xuezhikang group (n=306) and the placebo group (n=285). During the average 4 years of follow-up, there were 28 cases of CHD events (9.2%) in the xuezhikang group and 53 cases (18.6%) in the placebo group. Risk reduction for CHD events was 50.8% (P<0.001) by xuezhikang treatment. Xuezhikang decreased the risk of non-fatal MI by 63.8%, fatal MI by 58.5%, CHD sudden death by 26.9%, and other CHD death by 53.4%. CHD death totaled to 21 cases in the xuezhikang group (6.9%) and 35 cases in the placebo group (12.3%), indicating that xuezhikang significantly decreased the risk of CHD death by 44.1% (P<0.05). Seventy-two patients died from various causes, among which there were 27 patients in the xuezhikang group and 45 patients in the placebo group. The risk for all-cause death was 44.1% lower in the xuezhikang group than in the placebo group (P<0.01). This investigation demonstrates that xuezhikang therapy can be effective on reduction of cardiovascular events in diabetic patients with CHD with a reliable safety.

• Authors: Shui-ping Zhao, Zong-liang Lu, Bao-min Du, Zuo Chen, Yang-feng Wu, Xue-hai Yu, Yu-cheng Zhao, Ling Liu, Hui-jun Ye, Zhi-hong Wu, China Coronary Secondary Prevention Study (CCSPS)
• Journal: Journal of cardiovascular pharmacology (J Cardiovasc Pharmacol) Vol. 49 Issue 2 Pg. 81-4 (Feb 2007) ISSN: 0160-2446 [Print] United States
• PMID: 17312447 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Biological Products
• Drugs, Chinese Herbal
• Lipids
• red yeast rice
• xuezhikang

Topics

• Adolescent
• Adult
• Aged
• Biological Products (chemistry)
• China (epidemiology)
• Coronary Disease (drug therapy, mortality)
• Diabetes Mellitus, Type 2 (mortality)
• Diabetic Angiopathies (drug therapy, mortality)
• Double-Blind Method
• Drugs, Chinese Herbal (adverse effects, therapeutic use)
• Female
• Humans
• Lipids (blood)
• Liver Function Tests
• Male
• Middle Aged
• Myocardial Infarction (drug therapy, physiopathology)